CLAIMS

1. A compound of Formula (I):



(I),

or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof; wherein

X^1 and X^4 are each independently C or N;

X^2 and X^3 are each independently CR^5, N, NR^6, O, or S;

Y is CR^7, or N:

m and n are each independently an integer of 0, 1, or 2;

h and g are each independently an integer of 1 or 2;

d and f are each independently an integer of 0, 1, 2, or 3;

Z is 6- to 10-membered aryl, 5- to 10-membered heteroaryl, 3- to 10-membered carbocyclyl, or 4- to 10-membered heterocyclyl, wherein the aryl, heteroaryl carbocyclyl, and heterocyclyl are independently substituted with 0 to 5 R^8;

L^1 is a covalent bond, O, S, NR^{17}, $–S(O)_2–$, $C_{1–3}$ alkylene, $C_{1–3}$ heteroalkylene, $C_{2–4}$ alkenylene, $C_{2–4}$ alkynylene, aryl, or a 5- to 6-membered heteroaryl containing 1 to 4 heteroatoms independently selected from N, O, and S; wherein the alkylene, heteroalkylene, aryl, and heteroaryl are each independently substituted with 0 to 3 R^{11};

L^2 is a covalent bond, O, S, NR^{18}, $C_{1–3}$ alkylene, or $C_{1–3}$ heteroalkylene, wherein the alkylene and heteroalkylene are independently substituted with 0 to 3 R^{16};

R^X is $–L^3\text{-}R^Z$;

L^3 is a covalent bond, $C_{1–3}$ alkylene, or $–C(O)NR^{12}\text{-}CH_2–$, wherein the $C_{1–3}$ alkylene is substituted with 0 to 3 R^{15};

R^Z is –CN, $–C(O)OR^{13}$, $–C(O)NR^{14a}R^{14b}$,



R^e is $C_{1–6}$ alkyl, $C_{3–6}$ cycloalkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, or haloalkoxyalkyl;

R^{Y1} and R^{Y2} are each independently hydrogen, halo, cyano, hydroxyl, amino, $C_{1–6}$ alkyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy; or alternatively two R^{Y1}, together with the carbon atoms to which they are attached, form a bridge moiety; and with the proviso that when Y is N and R^{Y1} is attached to a carbon atom adjacent to Y, then R^{Y1} is not halo, cyano, hydroxyl, amino, alkoxy, or haloalkoxy;

R^1 is $C_{1–6}$ alkyl, $C_{3–5}$ cycloalkyl, or $C_{4–6}$ heterocyclyl, wherein the alkyl and cycloalkyl are independently substituted with 0 to 3 R^9;

R^2 is 6- to 10-membered aryl, 5- to 10-membered heteroaryl, 3- to 10-membered carbocyclyl, or 4- to 10-membered heterocyclyl, wherein the aryl, heteroaryl, carbocyclyl, and heterocyclyl are independently substituted with 0 to 5 R^{10};

R^3 and R^4 are each independently hydrogen, $C_{1–6}$ alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, or haloalkoxyalkyl;

R^5 and R^7 are each independently hydrogen, halo, cyano, hydroxyl, amino, $C_{1–6}$ alkyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy;

R^6, R^{17} and R^{18} are each independently hydrogen, $C_{1–6}$ alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy;

R^8 and R^{10} are each independently halo, cyano, hydroxyl, amino, oxo, $–OR^a$, $–SR^a$, =S, $–NR^cR^c$, =NH, =N-OH, $=NR^a$, $=N-OR^a$, $–NO_2$, $–S(O)_2R^a$, $–S(O)_2NHR^b$, $–S(O)_2NR^cR^c$, $–S(O)_2OR^b$, $–OS(O)_2R^b$, $–OS(O)_2OR^b$, $–P(O)(OR^b)(OR^b)$, $–C(O)R^b$, $–C(NR^b)R^b$,

$-C(O)OR^b$, $-C(O)NR^cR^c$, $-C(NR^b)NR^cR^c$, $-OC(O)R^b$, $-NR^bC(O)R^b$, $-OC(O)OR^b$, $-NR^bC(O)OR^b$, $-OC(O)NR^cR^c$, $-NR^bC(O)NR^cR^c$, $-NR^bC(NR^b)R^b$, $-NR^bC(NR^b)NR^cR^c$, C_{1-6} alkyl, C_{1-6} haloalkyl, aryl, arylalkyl, heteroaryl, carbocyclyl, or heterocyclyl; wherein the alkyl, aryl, heteroaryl, carbocyclyl, and heterocyclyl, by themselves or as part of another group, are each independently substituted with 0 to 5 R^d;

R^a is each independently C_{1-6} alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, carbocyclyl, carbocyclylalkyl, heterocyclyl, or heterocyclylalkyl;

R^b is each independently hydrogen or R^a;

R^c is each independently R^b or alternatively, the two R^c are taken together with the nitrogen atom to which they are bonded form a 4-, 5-, 6- or 7-membered heterocyclyl;

R^d is each independently R^a, alkoxy, haloalkoxy, alkylamino, cycloalkylamino, heterocyclylamino, haloalkyl, hydroxyalkyl, aminoalkyl, cycloalkoxy, heterocyclyloxy, haloalkoxy, alkoxyalkoxy, haloalkylamino, alkoxyalkylamino, haloalkoxyalkylamino, arylamino, aralkylamino, aryloxy, aralkyloxy, heteroaryloxy, heteroarylalkyloxy, alkylthio, halo, cyano, hydroxyl, amino, oxo, $-OR^a$, $-SR^a$, =S, $-NR^cR^c$, =NH, =N-OH, $=NR^a$, $=N-OR^a$, $-NO_2$, $-S(O)_2R^a$, $-S(O)_2NHR^b$, $-S(O)_2NR^cR^c$, $-S(O)_2OR^b$, $-OS(O)_2R^b$, $-OS(O)_2OR^b$, $-P(O)(OR^b)(OR^b)$, $-C(O)R^b$, $-C(NR^b)R^b$, $-C(O)OR^b$, $-C(O)NR^cR^c$, $-C(NR^b)NR^cR^c$, $-OC(O)R^b$, $-NR^bC(O)R^b$, $-OC(O)OR^b$, $-NR^bC(O)OR^b$, $-NR^bC(O)NR^cR^c$, $-NR^bC(NR^b)R^b$, or $-NR^bC(NR^b)NR^cR^c$;

R^9 is each independently halo, cyano, hydroxyl, amino, or C_{1-6} alkyl;

R^{11} and R^{16} are each independently halo, oxo, cyano, hydroxyl, amino, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{4-6} heterocyclyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy;

R^{12} are each independently hydrogen or C_{1-4} alkyl; and

R^{13} is hydrogen, C_{1-10} alkyl, or glycosyl;

R^{14a} and R^{14b} are each independently hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{4-6} heterocyclyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy; and

R^{15} are each independently halo, oxo, cyano, hydroxyl, amino, alkyl, alkoxy, or alkylamino; or alternatively, two R^{15}, taken together with the atom(s) to which they are attached, form a carbocyclyl or heterocyclyl moiety.

2. The compound of claim 1, wherein



the moiety is a ring moiety is


, 
, or 
.

3. The compound of any one of claims 1 to 2, wherein the



moiety is:


, 
, 
, or 
.

4. The compound of any one of claims 1 to 3, wherein Z is phenyl or 5- to 10-membered heteroaryl, wherein the phenyl and heteroaryl are independently substituted with 0 to 5 R^8.

5. The compound of any one of claims 1 to 3, wherein:

L^1 is a covalent bond; and

-Z-R^x is selected from:



wherein the Z moiety is further substituted with 0 to 3 R^8.

6. The compound of any one of claims 1 to 9, wherein:

L^2 is a covalent bond; and

R^2 is phenyl or 6-membered heteroaryl, wherein the phenyl and heteroaryl are independently substituted with 0 to 5 R^{10}.

7. The compound of claim 1, which is represented by Formula (II):



(II),

X^1 is C or N;

X^2 and X^3 are each independently CH, N, O, or S;

Z is phenyl or a 5- to 10-membered heteroaryl, wherein the phenyl and heteroaryl are independently substituted with 0 to 3 R^8;

R^X is $-C(O)OR^{13}$;

each R^Y is independently hydrogen, halo, cyano, hydroxyl, amino, C_{1-6} alkyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy;

f is an integer of 0, 1, or 2;

R^1 is C_{1-6} alkyl or C_{3-5} cycloalkyl, wherein the alkyl and cycloalkyl are independently

substituted with 0 to 3 R^9;

R^2 is phenyl or 6-membered heteroaryl, wherein the phenyl and heteroaryl are independently substituted with 0 to 3 R^{10}.

8. The compound according to claim 1, wherein:

X^1 is C;

X^2 is N;

X^3 is O;

X^4 is C;



moiety is  or 

;

L^1 is a covalent bond or $–CH_2O–$;

Z is phenyl, pyrazolyl, pyridinyl, benzo[d]thiazolyl, thiazolo[5,4-b]pyridinyl, quinolinyl, isoquinolinyl, cinnolinyl, or naphthyridinyl, each substituted with 0 to 2 R^8;

R^X is –CN, –C(O)OH, $–CH_2C(O)OH$, or $–C(O)NH_2$;

R^1 is cyclopropyl;

L^2 is a covalent bond;

R^2 is phenyl or pyridinyl, each substituted with 1 or 2 R^{10};

R^3 is hydrogen;

R^4 is hydrogen;

R^8 is each independently F, $–CH_3$, $–CH_2CH_3$, $–CH(CH_3)_2$, $–CF_3$, $–CH_2OCH_3$, $–OCH_3$, $–OCD_3$, $–OCH_2CH_3$, $–OCH(CH_3)_2$, cyclopropyl, methylpiperazinyl, –O(cyclopropyl), –O(cyclobutyl), –O(fluorocyclobutyl), –O(oxetanyl), or –O(tetrahydrofuranyl); and

R^{10} is each independently Cl or $–CF_3$.

9. The compound of claim 1, which is selected from any one of:

(E)-6-(6-(2-(5-Cyclopropyl-3-(3,5-dichloropyridin-4-yl)isoxazol-4-yl)vinyl)-2-azaspiro[3.3]heptan-2-yl)-4-methoxyquinoline-2-carboxylic acid (1);

(E)-6-(6-(2-(3-(3-chloropyridin-4-yl)-5-cyclopropylisoxazol-4-yl)vinyl)-2-

azaspiro[3.3]heptan-2-yl)-4-methoxyquinoline-2-carboxylic acid;

(*E*)-4-Cyclobutoxy-6-(6-(2-(5-cyclopropyl-3-(2-(trifluoromethyl)pyridin-3-yl)isoxazol-4-yl)vinyl)-2-azaspiro[3.3]heptan-2-yl)quinoline-2-carboxylic acid;

(E)-6-(6-(2-(5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)vinyl)-2-azaspiro[3.3]heptan-2-yl)-4-(trifluoromethyl)quinoline-2-carboxylic acid;

(E)-4-(6-(2-(5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)vinyl)-2-azaspiro[3.3]heptan-2-yl)benzoic acid;

(E)-6-(6-(2-(3-(3-chloropyridin-4-yl)-5-cyclopropylisoxazol-4-yl)vinyl)-2-azaspiro[3.3]heptan-2-yl)-4-(trifluoromethyl)quinoline-2-carboxylic acid;

(E)-6-(6-(2-(5-cyclopropyl-3-(3,5-dichloropyridin-4-yl)isoxazol-4-yl)vinyl)-2-azaspiro[3.3]heptan-2-yl)-4-(trifluoromethyl)quinoline-2-carboxylic acid;

(E)-6-(6-(2-(5-cyclopropyl-3-(2-(trifluoromethyl)phenyl)isoxazol-4-yl)vinyl)-2-azaspiro[3.3]heptan-2-yl)-4-(trifluoromethyl)quinoline-2-carboxylic acid;

(E)-2-(6-(2-(5-cyclopropyl-3-(2-(trifluoromethyl)phenyl)isoxazol-4-yl)vinyl)-2-azaspiro[3.3]heptan-2-yl)-7-methylthiazolo[5,4-b]pyridine-5-carboxylic acid;

(E)-2-(6-(2-(5-cyclopropyl-3-(3,5-dichloropyridin-4-yl)isoxazol-4-yl)vinyl)-2-azaspiro[3.3]heptan-2-yl)-4-fluorobenzo[d]thiazole-6-carboxylic acid;

(E)-6-(6-(2-(5-cyclopropyl-3-(3,5-dichloropyridin-4-yl)isoxazol-4-yl)vinyl)-2-azaspiro[3.3]heptan-2-yl)-4-isopropoxyquinoline-2-carboxylic acid;

(E)-6-(6-(2-(5-cyclopropyl-3-(2-(trifluoromethyl)phenyl)isoxazol-4-yl)vinyl)-2-azaspiro[3.3]heptan-2-yl)-4-isopropoxyquinoline-2-carboxylic acid;

(E)-7-(6-(2-(5-cyclopropyl-3-(3,5-dichloropyridin-4-yl)isoxazol-4-yl)vinyl)-2-azaspiro[3.3]heptan-2-yl)-1-methylisoquinoline-3-carboxylic acid;

(E)-7-(6-(2-(5-cyclopropyl-3-(3,5-dichloropyridin-4-yl)isoxazol-4-yl)vinyl)-2-azaspiro[3.3]heptan-2-yl)-1-ethylisoquinoline-3-carboxylic acid;

(E)-6-(6-(2-(5-cyclopropyl-3-(3-(trifluoromethyl)pyridin-2-yl)isoxazol-4-yl)vinyl)-2-azaspiro[3.3]heptan-2-yl)-4-isopropoxyquinoline-2-carboxylic acid;

(E)-6-(6-(2-(5-cyclopropyl-3-(2-(trifluoromethyl)phenyl)isoxazol-4-yl)vinyl)-2-azaspiro[3.3]heptan-2-yl)-4-methoxyquinoline-2-carboxylic acid;

(E)-4-cyclobutoxy-6-(6-(2-(5-cyclopropyl-3-(3,5-dichloropyridin-4-yl)isoxazol-4-yl)vinyl)-2-azaspiro[3.3]heptan-2-yl)quinoline-2-carboxylic acid;

(E)-6-(6-(2-(5-cyclopropyl-3-(2-(trifluoromethyl)phenyl)isoxazol-4-yl)vinyl)-2-azaspiro[3.3]heptan-2-yl)-4-(oxetan-3-yloxy)quinoline-2-carboxylic acid;

(E)-7-(6-(2-(5-cyclopropyl-3-(2-(trifluoromethyl)phenyl)isoxazol-4-yl)vinyl)-2-azaspiro[3.3]heptan-2-yl)-1-methoxyisoquinoline-3-carboxylic acid;

(R,E)-6-(6-(2-(5-cyclopropyl-3-(2-(trifluoromethyl)phenyl)isoxazol-4-yl)vinyl)-2-azaspiro[3.3]heptan-2-yl)-4-((tetrahydrofuran-3-yl)oxy)quinoline-2-carboxylic acid;

(S,E)-6-(6-(2-(5-cyclopropyl-3-(2-(trifluoromethyl)phenyl)isoxazol-4-yl)vinyl)-2-azaspiro[3.3]heptan-2-yl)-4-((tetrahydrofuran-3-yl)oxy)quinoline-2-carboxylic acid;

(E)-6-(6-(2-(5-cyclopropyl-3-(2-(trifluoromethyl)pyridin-3-yl)isoxazol-4-yl) vinyl)-2-azaspiro[3.3]heptan-2-yl)-4-methoxyquinoline-2-carboxylic acid;

(E)-6-(6-(2-(5-cyclopropyl-3-(2-(trifluoromethyl)pyridin-3-yl)isoxazol-4-yl) vinyl)-2-azaspiro[3.3]heptan-2-yl)-4-(oxetan-3-yloxy)quinoline-2-carboxylic acid;

(E)-6-(6-(2-(5-cyclopropyl-3-(3,5-dichloropyridin-4-yl)isoxazol-4-yl)vinyl)-2-azaspiro[3.3]heptan-2-yl)-4-(oxetan-3-yloxy)quinoline-2-carboxylic acid;

(E)-6-(6-(2-(5-cyclopropyl-3-(2-(trifluoromethyl)pyridin-3-yl)isoxazol-4-yl)vinyl)-2-azaspiro[3.3]heptan-2-yl)-4-ethoxyquinoline-2-carboxylic acid;

(R,E)-6-(6-(2-(5-cyclopropyl-3-(2-(trifluoromethyl)pyridin-3-yl)isoxazol-4-yl) vinyl)-2-azaspiro[3.3]heptan-2-yl)-4-((tetrahydrofuran-3-yl)oxy)quinoline-2-carboxylic acid;

(E)-6-(6-(2-(5-cyclopropyl-3-(3,5-dichloropyridin-4-yl)isoxazol-4-yl)vinyl)-2-azaspiro[3.3]heptan-2-yl)-4-(methoxymethyl)quinoline-2-carboxylic acid;

(E)-6-(6-(2-(5-cyclopropyl-3-(3,5-dichloropyridin-4-yl)isoxazol-4-yl)vinyl)-2-azaspiro[3.3]heptan-2-yl)-4-methoxy-1,5-naphthyridine-2-carboxylic acid;

(*E*)-5-((6-(2-(5-Cyclopropyl-3-(3,5-dichloropyridin-4-yl)isoxazol-4-yl)vinyl) spiro[3,3] heptan-2-yl)methoxy)-3-methylpicolinic acid;

(*E*)-5-((6-(2-(5-Cyclopropyl-3-(2-(trifluoromethyl)phenyl)isoxazol-4-yl)vinyl)spiro [3.3]heptan-2-yl)methoxy)-3-methylpicolinic acid;

(*E*)-5-((6-(2-(5-Cyclopropyl-3-(2-(trifluoromethyl)phenyl)isoxazol-4-yl)vinyl)spiro[3,3] heptan-2-yl)methoxy)-3-isopropoxypicolinic acid;

(*E*)-5-((6-(2-(5-Cyclopropyl-3-(2-(trifluoromethyl)phenyl)isoxazol-4-yl)vinyl)spiro[3,3] heptan-2-yl)methoxy)-3-isopropoxypicolinamide;

(E)-4-cyclopropoxy-6-(6-(2-(5-cyclopropyl-3-(3,5-dichloropyridin-4-yl)isoxazol-4-yl)vinyl)-2-azaspiro[3.3]heptan-2-yl)quinoline-2-carboxamide;

(E)-6-(6-(2-(5-cyclopropyl-3-(3,5-dichloropyridin-4-yl)isoxazol-4-yl) vinyl)-2-azaspiro[3.3]heptan-2-yl)-4-(methoxy-d3)quinoline-2-carboxylic acid;

(E)-6-(6-(2-(5-cyclopropyl-3-(3,5-dichloropyridin-4-yl)isoxazol-4-yl) vinyl)-2-azaspiro[3.3]heptan-2-yl)-4-methoxy-1,5-naphthyridine-2-carboxylic acid;

(E)-6-(6-(2-(5-cyclopropyl-3-(4-(trifluoromethyl)pyridin-3-yl) isoxazol-4-yl)vinyl)-2-azaspiro[3.3]heptan-2-yl)-4-methoxyquinoline-2-carboxylic acid;

6-(6-((E)-2-(5-cyclopropyl-3-(3,5-dichloropyridin-4-yl)isoxazol-4-yl)vinyl)-2-azaspiro[3.3]heptan-2-yl)-4-((1r,3r)-3-fluorocyclobutoxy)quinoline-2-carboxylic acid;

(E)-4-cyclopropoxy-6-(6-(2-(5-cyclopropyl-3-(3,5-dichloropyridin-4-yl)isoxazol-4-yl)vinyl)-2-azaspiro[3.3]heptan-2-yl)quinoline-2-carboxylic acid;

6-(6-((E)-2-(5-cyclopropyl-3-(3,5-dichloropyridin-4-yl)isoxazol-4-yl)vinyl)-2-azaspiro[3.3]heptan-2-yl)-4-((1s,3s)-3-fluorocyclobutoxy)quinoline-2-carboxylic acid;

(E)-6-(6-(2-(5-cyclopropyl-3-(3,5-dichloropyridin-4-yl)isoxazol-4-yl)vinyl)-2-azaspiro[3.3]heptan-2-yl)-8-fluoro-4-methoxyquinoline-2-carboxylic acid;

(E)-3-(6-(2-(5-cyclopropyl-3-(3,5-dichloropyridin-4-yl)isoxazol-4-yl)vinyl)-2-azaspiro[3.3]heptan-2-yl)-5-methoxybenzoic acid;

(E)-4-cyclopropoxy-6-(6-(2-(5-cyclopropyl-3-(3,5-dichloropyridin-4-yl)isoxazol-4-yl)vinyl)-2-azaspiro[3.3]heptan-2-yl)quinoline-2-carbonitrile;

(E)-4-cyclopropoxy-6-(6-(2-(5-cyclopropyl-3-(4-(trifluoromethyl)pyridin-3-yl)isoxazol-4-yl)vinyl)-2-azaspiro[3.3]heptan-2-yl)quinoline-2-carboxylic acid;

(E)-5-((6-(2-(5-cyclopropyl-3-(3,5-dichloropyridin-4-yl)isoxazol-4-yl)vinyl)spiro[3.3]heptan-2-yl)methoxy)-1-methyl-1H-pyrazole-3-carboxylic acid;

(E)-6-((6-(2-(5-cyclopropyl-3-(3,5-dichloropyridin-4-yl)isoxazol-4-yl)vinyl)spiro[3.3]heptan-2-yl)methoxy)-4-(trifluoromethyl) quinoline-2-carboxylic acid;

(E)-3-((6-(2-(5-cyclopropyl-3-(3,5-dichloropyridin-4-yl)isoxazol-4-yl)vinyl)spiro[3.3]heptan-2-yl)methoxy)benzoic acid;

(E)-3-((6-(2-(5-cyclopropyl-3-(2-(trifluoromethyl)phenyl)isoxazol-4-yl)vinyl)spiro[3.3]heptan-2-yl)methoxy)benzamide;

(E)-2-(4-((6-(2-(5-cyclopropyl-3-(2-(trifluoromethyl)phenyl) isoxazol-4-yl)vinyl)spiro[3.3]heptan-2-yl)methoxy)phenyl)acetamide;

(E)-5-((6-(2-(5-cyclopropyl-3-(2-(trifluoromethyl)phenyl)isoxazol-4-yl)vinyl)spiro[3.3]heptan-2-yl)methoxy)-3-methylpicolinic acid;

(E)-5-((6-(2-(5-cyclopropyl-3-(2-(trifluoromethyl)phenyl)isoxazol-4-yl)vinyl)spiro[3.3]heptan-2-yl)methoxy)-1-methyl-1H-pyrazole-3-carboxylic acid;

(E)-6-((6-(2-(5-cyclopropyl-3-(2-(trifluoromethyl)phenyl)isoxazol-4-

yl)vinyl)spiro[3.3]heptan-2-yl)methoxy)-4-(trifluoromethyl)quinoline-2-carboxylic acid;

(E)-6-((6-(2-(5-cyclopropyl-3-(2-(trifluoromethyl)phenyl)isoxazol-4-yl)vinyl) spiro[3.3]heptan-2-yl)methoxy)quinoline-2-carboxylic acid;

(E)-7-((6-(2-(5-cyclopropyl-3-(2-(trifluoromethyl)phenyl)isoxazol-4-yl)vinyl)spiro[3.3]heptan-2-yl)methoxy)cinnoline-3-carboxylic acid;

(E)-5-((6-(2-(5-cyclopropyl-3-(3,5-dichloropyridin-4-yl)isoxazol-4-yl) vinyl)spiro[3.3]heptan-2-yl)methoxy)-3-(trifluoromethyl)picolinic acid;

(E)-5-((6-(2-(5-cyclopropyl-3-(2-(trifluoromethyl)phenyl)isoxazol-4-yl)vinyl)spiro[3.3]heptan-2-yl)methoxy)-3-(trifluoromethyl)picolinic acid;

(E)-7-((6-(2-(5-cyclopropyl-3-(3,5-dichloropyridin-4-yl)isoxazol-4-yl)vinyl)spiro[3.3]heptan-2-yl)methoxy)cinnoline-3-carboxylic acid;

(E)-3-cyclobutoxy-5-((6-(2-(5-cyclopropyl-3-(3,5-dichloropyridin-4-yl)isoxazol-4-yl)vinyl)spiro[3.3]heptan-2-yl)methoxy)picolinic acid;

(E)-3-((6-(2-(5-cyclopropyl-3-(3,5-dichloropyridin-4-yl)isoxazol-4-yl) vinyl)spiro[3.3]heptan-2-yl)methoxy)-1-isopropyl-4-methyl-1H-pyrazole-5-carboxylic acid;

(E)-1-cyclopropyl-5-((6-(2-(5-cyclopropyl-3-(3,5-dichloropyridin-4-yl) isoxazol-4-yl)vinyl)spiro[3.3]heptan-2-yl)methoxy)-1H-pyrazole-3-carboxylic acid;

(E)-3-cyclopropoxy-5-((6-(2-(5-cyclopropyl-3-(2-(trifluoromethyl) phenyl)isoxazol-4-yl)vinyl)spiro[3.3]heptan-2-yl)methoxy)picolinic acid;

(E)-3-cyclobutoxy-5-((6-(2-(5-cyclopropyl-3-(2-(trifluoromethyl) phenyl)isoxazol-4-yl)vinyl)spiro[3.3]heptan-2-yl)methoxy)picolinic acid;

(E)-3-cyclobutoxy-5-((6-(2-(5-cyclopropyl-3-(2-(trifluoromethyl) phenyl)isoxazol-4-yl)vinyl)spiro[3.3]heptan-2-yl)methoxy) picolinamide;

(E)-3-cyclopropoxy-5-((6-(2-(5-cyclopropyl-3-(2-(trifluoromethyl) phenyl)isoxazol-4-yl)vinyl)spiro[3.3]heptan-2-yl)methoxy) picolinamide;

(E)-3-cyclobutoxy-5-((6-(2-(5-cyclopropyl-3-(3,5-dichloropyridin-4-yl)isoxazol-4-yl)vinyl)spiro[3.3]heptan-2-yl)methoxy)picolinamide;

(E)-6-((6-(2-(5-cyclopropyl-3-(3,5-dichloropyridin-4-yl)isoxazol-4-yl) vinyl)spiro[3.3]heptan-2-yl)methoxy)-4-(4-methylpiperazin-1-yl) quinoline-2-carboxylic acid; or

(E)-6-((6-(2-(5-cyclopropyl-3-(2-(trifluoromethyl)phenyl)isoxazol-4-yl)vinyl)spiro[3.3]heptan-2-yl)methoxy)-4-(4-methylpiperazin-1-yl) quinoline-2-carboxylic acid;

or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof.

10. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to any one of claims 1 to 9, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof.

11. A compound according to any one of claims 1 to 9 or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, for use in therapy.

12. A compound according to any one of claims 1 to 9 or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, for use in therapy in treating pathological fibrosis, cancer, inflammatory disorders, metabolic, or cholestatic disorders.

13. The compound or stereoisomer, a tautomer, or pharmaceutically acceptable salt or solvate thereof for use according to claim 12, wherein the pathological fibrosis is liver fibrosis, renal fibrosis, biliary fibrosis, or pancreatic fibrosis.

14. A compound according to any one of claims 1 to 9 or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, for use in therapy in treating nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis (PSC), or primary biliary cirrhosis (PBC).

15. A compound according to any one of claims 1 to 9 or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, for use in therapy in treating idiopathic pulmonary fibrosis (IPF).